What It Takes to Commercialize Medical Innovation in Minnesota
Over more than three decades leading medical technology companies, I’ve seen firsthand that developing a promising medical device is often easier than building a sustainable business around it. Minnesota has spent decades building a strong medical technology ecosystem anchored by the University of Minnesota, Mayo Clinic, and an established medical device industry. The state’s research institutions, healthcare systems, and experienced medtech workforce have helped make it an important center for medical innovation.
The state’s MedTech 3.0 initiative identifies Minnesota as having the highest concentration of medtech workers in the country. Minnesota also attracted $1.1 billion in venture capital across 166 deals in 2025, including $398 million across 49 deals in healthcare devices and supplies, according to state economic development data.
The next challenge is helping more companies turn promising ideas into technologies that clinicians will use, healthcare providers will invest in, and patients can benefit from.
Minnesota’s Advantage Is Its Depth of Expertise
Minnesota’s medical device industry has developed expertise across mechanical engineering, software and firmware, quality systems, regulatory affairs, and clinical research. The University of Minnesota and Mayo Clinic contribute research capabilities and clinical insight, while established device companies offer experience navigating the demands of regulated product development.
This expertise helps entrepreneurs identify clinical needs, connect with physicians, and recruit people who understand the demands of bringing a medical device to market. Clinicians are particularly important in identifying where existing approaches fall short and defining what a new technology must accomplish in real-world care.
But strong research and technical capabilities are only part of the equation. Companies must also determine how to validate their products, demonstrate their value, and fund the work required to bring them into routine clinical use. Those considerations need to shape a commercialization strategy early, rather than being addressed only after technology has been developed.
Commercialization Requires More Than Regulatory Clearance
Medical device companies must navigate regulatory requirements, generate clinical evidence, and establish credible cases for the economic value of their products. These are connected challenges, and progress in one area does not automatically resolve the others.
From a company’s perspective, meeting regulatory requirements is one milestone in a much longer process. The next challenge is generating the evidence clinicians need to trust a technology and healthcare providers need to justify adopting it.
For devices that follow the FDA’s 510(k) pathway, companies must demonstrate that their device is substantially equivalent to a legally marketed device. Clearance, however, does not guarantee widespread adoption. Physicians need confidence that technology performs as intended and addresses a meaningful clinical need. Hospitals and other healthcare providers also need to understand how it fits into existing workflows and whether its benefits justify the cost.
Companies should plan early for the evidence they will need to answer those questions. Depending on the technology, that may include clinical studies, post-market research, and publications documenting early clinical experience. Working with clinicians throughout development can help companies identify relevant outcomes and build a stronger understanding of how a device performs in practice.
Economic evidence is equally important. If a company expects its technology to reduce hospital expenses, save clinicians time, or improve the use of healthcare resources, it must be prepared to substantiate those claims. Demonstrating clinical value and making a credible economic case can help providers evaluate a technology’s place in care.
Planning for these requirements early can help companies avoid costly delays and build a stronger case for adoption.
Closing the Gap Between Early Investment and Commercialization
According to the Minnesota Department of Employment and Economic Development (DEED), Minnesota attracted $1.1 billion in venture capital across 166 deals in 2025, including $398 million across 49 deals in healthcare devices and supplies. Total venture investment fell 36% from the previous year, even as the number of transactions increased. While these figures reflect the broader investment environment, they don’t show how difficult it can be for medical technology companies to secure funding as they advance toward commercialization.
In my experience, securing capital becomes particularly challenging as companies move beyond the earliest stages and seek Series A or Series B financing. Early-stage investors can help businesses get started, but companies often need substantially more capital to fund clinical validation, regulatory milestones, manufacturing preparation, and commercialization, frequently before they have established a reliable revenue stream.
One of the most difficult funding gaps occurs when a company has successfully developed its technology but has not yet demonstrated sustained commercial adoption. At that stage, the technical risks may be declining, but investors are being asked to finance manufacturing, clinical adoption, and the time required to build a recurring revenue business
When follow-on financing is difficult to secure, businesses may have to slow development or struggle to reach the milestones needed to attract additional investors. This can leave promising technologies short of the funding needed to progress, even when a clinical need and a potential market exist.
States across the country are navigating the same issues, which can serve as a guide for how states like Minnesota support companies through these transitions. Massachusetts, for example, has introduced a grant program to help early-stage life sciences companies access specialized support for regulatory planning, reimbursement strategy, market validation, and manufacturing readiness.
Minnesota has an opportunity to continue to distinguish itself not only as a place where medical technologies are invented, but also as a place where emerging companies can successfully commercialize them. Targeted support for regulatory strategy, reimbursement planning, clinical validation, and manufacturing readiness could complement existing startup programs and help companies reach the milestones needed to attract private investment.
Turning Minnesota’s Strengths into Lasting Impact
Minnesota has the institutions, talent, and industry experience to continue developing important medical technologies. The opportunity is to help more companies navigate the steps between a promising idea and a product that can succeed in clinical practice. That requires planning for commercialization early, demonstrating clinical and economic value, and ensuring companies can access the expertise and capital needed to advance.
Minnesota has already demonstrated that it can invent world-class medical technologies. The next opportunity is to become equally successful at helping emerging companies bring those innovations into clinical practice. Our state’s success should be measured not simply by the number of companies we start or patents we generate, but by the technologies that reach patients, improve care, and create sustainable businesses here in Minnesota.